company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,530000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,530000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,530000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2335000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1890000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4225000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3695000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3695000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3695000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,112000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3583000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3583000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,39800000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.09
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,39800000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.09
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39493000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:37:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.09
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,351000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,351000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,351000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,445000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1541000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1986000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1635000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1636000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1636000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-36000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1672000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1672000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41800000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41800000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39507000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 16:34:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,395000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,395000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,395000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,569000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1141000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1710000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1315000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1316000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1316000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-103000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1419000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1419000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35500000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35500000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39869.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 13:57:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,251000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,251000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,251000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,509000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1282000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1791000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1540000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-263000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-263000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1803000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1803000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-129000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1932000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1932000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38600000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.05
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38600000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.05
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,40016000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 13:14:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.05
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1160000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2929000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4089000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4089000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-62000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-62000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4151000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4151000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-51000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4202000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4202000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,210100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,210100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,198279000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q3,2011-07-01,2011-09-30,2011-11-07 16:34:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1263000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2855000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4118000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4118000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-47000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-47000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4165000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4165000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-96000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4261000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4261000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,118100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,118100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,120263000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1440000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3329000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4769000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4769000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-61000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-61000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4830000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4830000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-91000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4921000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4921000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,246100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,246100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200046.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 13:57:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1313000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3067000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4380000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4380000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-146000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-146000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4526000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4526000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-43000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4569000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4569000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,228500000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,228500000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200112000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q2,2012-04-01,2012-06-30,2012-08-09 13:14:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2428000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3626000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6054000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6054000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-195000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-195000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6249000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6249000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,128000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6121000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6121000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,306100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,306100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,274488000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 08:46:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.02
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3605000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5023000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8628000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8628000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-197000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-197000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8825000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8825000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,1088000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7737000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7737000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,233500000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.03
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,233500000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.03
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,233500000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.03
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5980000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6772000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12752000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12752000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-201000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-201000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12953000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12953000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12953000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12953000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,323800000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,323800000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,305075000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q1,2013-01-01,2013-03-31,2013-05-10 14:34:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4678000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10531000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15209000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15209000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-204000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-204000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15413000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15413000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15413000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15413000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,308300000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.05
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,308300000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.05
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,305690000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q2,2013-04-01,2013-06-30,2013-08-08 06:08:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.05
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6779000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5885000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12664000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12664000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-209000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-209000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12873000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12873000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12873000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12873000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,321800000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,321800000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,307496000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q3,2013-07-01,2013-09-30,2013-11-12 08:46:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.04
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4504000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9328000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13832000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13832000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,828000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,614000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-212000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14044000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14044000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14044000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14044000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,16200000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.87
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16200000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.87
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,16163000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.87
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3587000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,2269000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14504000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20360000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20360000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,210000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-210000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20570000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20570000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20570000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20570000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29400000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.7
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29400000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.7
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29392000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.7
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4082000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,2757000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16175000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23014000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23014000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,93000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-93000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-23107000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-23107000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-23107000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-23107000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,31200000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.74
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,31200000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.74
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,31035000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:49:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.74
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4127000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,4123000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14241000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22491000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22491000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-181000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-181000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22672000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22672000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22672000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22672000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36000000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.63
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36000000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.63
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35773000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q3,2015-07-01,2015-09-30,2016-11-08 16:31:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.63
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6599000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,8198000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16263000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31060000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-31060000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,655000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,174000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,299000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-182000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-31242000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-31242000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-31242000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-31242000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.94
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.94
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33081000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.94
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5367000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,11853000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16092000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33312000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-33312000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,133000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-133000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-33445000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-33445000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-33445000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-33445000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36400000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.92
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36400000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.92
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,36229000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q1,2016-01-01,2016-03-31,2017-05-10 08:16:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.92
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4774000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,11006000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,27286000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,43066000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-43066000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-160000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-160000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-43226000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-43226000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-43226000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-43226000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36900000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.17
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36900000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.17
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37048000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:35:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.17
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5333000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,12159000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,30242000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,47734000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-47734000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-47734000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-775000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-48509000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-48509000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-48509000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,39100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.24
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,39100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.24
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39113000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 08:46:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.24
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1279000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1279000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,35000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,35000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1244000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5892000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,12650000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,29505000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,48047000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-46803000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2531000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,605000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-9000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1935000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-48738000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,775000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-47963000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-47963000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-47963000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38000000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.23
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38000000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.23
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37925000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.23
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3632000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3632000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1186000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1186000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2446000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6742000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,11619000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,33384000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,51745000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-49299000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1030000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1030000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-50329000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-50329000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-50329000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-50329000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50300000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,50300000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50530000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q1,2017-01-01,2017-03-31,2017-05-10 08:16:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8510000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8510000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1013000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1013000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7497000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6185000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,14770000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,28597000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,49552000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-42055000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-744000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-744000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-42799000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-42799000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-42799000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-42799000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,53500000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.8
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53500000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.8
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,53791000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 16:35:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.8
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8572000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8572000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1051000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1051000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7521000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6462000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,13529000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,28844000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,48835000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-41314000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-552000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-552000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-41866000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-41866000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-41866000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-41866000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,54400000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.77
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,54400000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.77
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,54176000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q3,2017-07-01,2017-09-30,2017-11-06 08:46:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.77
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10053000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10053000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1338000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1338000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8715000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6165000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,16683000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,47757000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,70605000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-61890000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2907000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2345000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-38000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-600000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-62490000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-62490000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-62490000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-62490000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,54100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.08
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,54100000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.08
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,54040000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.08
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11567000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11567000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3133000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3133000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8434000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7028000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,13835000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,39561000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,60424000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-51990000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-275000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-275000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-52265000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-52265000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-52265000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-52265000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,64500000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.81
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,64500000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.81
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,64724000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 08:40:05+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.81
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,17277000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,17277000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5231000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5231000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12046000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6209000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,14531000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,30159000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,50899000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-38853000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,183000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,183000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-38670000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-38670000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-38670000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-38670000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,71600000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.54
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,71600000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.54
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,71952000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q2,2018-04-01,2018-06-30,2019-08-05 08:46:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.54
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19786000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19786000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7576000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7576000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12210000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7288000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,16281000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,30421000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,53990000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-41780000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3434000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3434000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-38346000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-38346000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-38346000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-38346000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,78300000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.49
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,78300000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.49
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,77811000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 08:46:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.49
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,28844000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,28844000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,11572000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,11572000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17272000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8738000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,19957000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,39891000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,68586000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-51314000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2672000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5965000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1538000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1755000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-49559000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-49559000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-49559000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-49559000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,73300000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.6
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,73300000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.6
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,73193000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.6
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,31602000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,31602000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14962000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14962000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16640000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9648000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,28720000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,42972000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,81340000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-64700000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1688000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1688000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-63012000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-63012000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-63012000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-63012000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,78800000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.8
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,78800000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.8
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,78419000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q1,2019-01-01,2019-03-31,2020-05-06 09:16:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.8
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,36659000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,36659000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,13588000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,13588000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,23071000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9778000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,23647000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,41425000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,74850000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-51779000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1557000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1557000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-50222000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-50222000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-50222000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-50222000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,79700000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.63
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,79700000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.63
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,79548000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q2,2019-04-01,2019-06-30,2019-08-05 08:46:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.63
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,42624000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,42624000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,17195000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,17195000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,25429000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8597000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,16977000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,34708000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,60282000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-34853000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1258000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1258000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-33595000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-33595000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-33595000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-33595000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,80000000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.42
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,80000000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.42
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,79940000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 08:46:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.42
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,35083000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,35083000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,15874000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,15874000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,19209000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9874000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,20420000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,48277000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,78571000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-59362000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1472000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,7259000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-4345000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1442000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-57920000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-57920000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-57920000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-57920000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,81900000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.65
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,81900000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.65
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,81779000.0
Heron Therapeutics Inc,HRTX,549300DR2I1DOPD2IX53,0000818033,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.65
